VAX 014
Alternative Names: VAX-014Latest Information Update: 28 Mar 2025
At a glance
- Originator Vaxiion Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses; Recombinant proteins
- Mechanism of Action Apoptosis stimulants; Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Bladder cancer
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for phase-I development in Bladder-cancer in USA (Intravesicular, Infusion)
- 28 Mar 2025 No recent reports of development identified for research development in Solid-tumours in USA (Intravesicular, Injection)
- 02 Nov 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (Intratumoural) (NCT05901285)